SARS-CoV-2

References 2024 & 2025

• Functional T cell response to COVID-19 vaccination with or without natural infection with SARS-CoV-2 in adults and children
  Ahtar et al., Scientific Reports (2025) - PMID: 40247005
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
  
• Endemic coronavirus infection is associated with SARS-CoV-2 Fc receptor-binding antibodies
  Bean et al., Journal of Virology (2025) - PMID: 40387363
  Products used: PepMix™ SARS-CoV-2 (Nsp12) and PepMix™ SARS-CoV-2 (Nsp13)
• Immunological memory in infected & exposure näive individuals one year post SARS-CoV-2 vaccination
  Das et al., Indian Journal of Medical Research (2025) - PMID: 40347503
  Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
• CD55 upregulation in T cells of COVID-19 patients suppresses type-I interferon responses
  Detsika et al., Communications Biology (2025) - PMID: 40316776
  Products used: PepMix™ SARS-CoV-2 (Spike XBB.1.5), PepMix™ SARS-CoV-2 (NCAP B1.1.529 / BA.1 / Omicron)
• Longitudinal analysis of immune responses to SARS-CoV-2 recombinant vaccine S-268019-b in phase 1/2 prime-boost study
  Fujitani et al., Frontiers in Immunology (2025) - PMID: 40109335
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
• HA-ppy immunity: unveiling the power of hyaluronan as an adjuvant in SARS-CoV-2 vaccination
  Genova, Dissertation (2025) 
  Product used: PepMix™ SARS-CoV-2 (S-RBD)
• Immune profiling after SARS-CoV-2 infection: Investigation of T cell reactivity in convalescent individuals and persistent immune abnormalities in post-COVID Patients
  Gilberg, Dissertation (2025) 
  Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
• Long-term mitochondrial and metabolic impairment in lymphocytes of subjects who recovered after severe COVID-19
  Gómez‑Delgado et al., Cell Biology and Toxicology (2025) - PMID: 39792183
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
• COVID-19 and SARS-CoV-2 vaccination related T cell immune response in diverse populations
  Gupta, Dissertation (2025) 
  Product used: PepMix™ SARS-CoV-2 (NCAP)
• Celluloepidemiology—A paradigm for quantifyinginfectious disease dynamics on a population level
  Ha et al., Science Advances (2025) - PMID: 40378227
  Product used: Custom PepMix
• A bivalent COVID-19 mRNA vaccine elicited broad immune responses and protection against Omicron subvariants infection
  Liu et al., NPJ Vaccines (2025) - PMID: 39788981
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein), PepMix™ SARS-CoV-2 (Spike B.1.1.529 / BA.4 & BA.5 / Omicron), PepMix™ SARS-CoV-2 (Spike XBB.1.5), PepMix™ SARS-CoV-2 (Spike JN.1)
• Generation of an inflammatory niche in a hydrogel depot through recruitment of key immune cells improves efficacy of mRNA vaccines
  Meany et al., Science Advances (2025) - PMID: 40215318
  Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
• Vaccination against SARS-CoV-2 provides low-level crossprotection against common cold coronaviruses in mouse and non-human primate animal models
  Naghibosadat et al., Journal of Virology (2025) - PMID: 39817773
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein), PepMix™ HCoV-229E (Spike Glycoprotein)
• Immune disturbances in individuals with post-COVID syndrome are not characterized by enhanced SARS-CoV-2-specific immunity
  Ober et al., Journal of Infectious Diseases (2025) - PMID: 40279368
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
• Pregnancy Reduces COVID-19 Vaccine Immunity Against Novel Variants
  Parish et al., MedRxiv (2025)
  Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
• Modifying the glycosylation profile of SARS-CoV-2 spike-based subunit vaccines alters focusing of the humoral immune response in a mouse model
  Renner et al., Communications Medicine (2025) - PMID: 40217109
  Product used: PepTrack Peptide Libraries
• Cellular and humoral immunity towards SARS-CoV-2 infection and vaccination in patients with primary antibody deficiency
  Steiner, Dissertation (2025)
  Product used: PepMix™ SARS-CoV-2 (NCAP), PepMix™ HCoV-OC43 (Spike Glycoprotein), PepMix™ HCoV-229E (Spike Glycoprotein), PepMix™ SARS-CoV-2 (Spike Glycoprotein)
• Alphaviral genetic background of self-amplifying RNA enhances protein expression and immunogenicity against SARS-CoV-2 antigen
  Casmil et al., Molecular Therapy (2024) 
  Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
• Comparison of a SARS-CoV-2 mRNA booster immunization containing additional antigens to a spike-based mRNA vaccine against Omicron BA.5 infection in hACE2 mice
  Hurst et al., PLoS One (2024) - PMID: 39625929
  Product used: PepMix™ SARS-CoV-2 (Spike B.1.351 / Beta)
• T Cell Responses to BA.2.86 and JN.1 SARS-CoV-2 Variants in Elderly Subjects
  Segato et al., Vaccines (2024)
  Products used: PepMix™ SARS-CoV-2 (S-RBD), PepMix™ SARS-CoV-2 (S-RBD BA.2.86)
• Effect of XBB.1.5-adapted booster vaccination on the imprinting of SARS-CoV-2 immunity
  Pušnik et al., Vaccines (2024) - PMID: 39572559
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein), PepMix™ SARS-CoV-2 (Spike XBB.1.5)
• Adjuvants to the S1-subunit of the SARS-CoV-2 spike protein vaccine improve antibody and T cell responses and surrogate neutralization in mice
  Becker et al., Scientific Reports (2024)
  Product used: PepMix™ SARS-CoV-2 (S-RBD)
• Antibodies in Infectious Diseases: HIV Biomarker Discoveries, Complement Enhanced SARS-CoV-2 Neutralization and Vaccine Generation
  Buylowski et al., Dissertation (2024) 
  Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
• Suppression of Type I Interferon Signaling in Myeloid Cells by Autoantibodies in Severe COVID‑19 Patients
  Aoki et al., Journal of Clinical Immunology (2024) - PMID: 38647550
  Products used: Custom PepStar
• Autoantibodies to ACE2 and immune molecules are associated with COVID-19 disease severity
  Geanes et al., Communications Medicine (2024) - PMID: 38491326
  Product used: Custom PepStar 
• Antigen clustering effect on immunogenicity in prefusion-stabilized spike-based COVID-19 vaccines
  Matthews et al., Research Square (2024) 
  Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1)
• Engineered protein subunit COVID19 vaccine is as immunogenic as nanoparticles in mouse and hamster models
  Matthews et al., Scientific Reports (2024) 
  Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
• A Robust SARS-CoV-2-specific T and B Cell Response is Associated with Early Viral Clearance in SARS-CoV-2 Infected Immunocompromised Individuals
  Vergouwe et al., Journal of Infectious Diseases (2024) - PMID: 38843052
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein), PepMix™ SARS-CoV-2 (NCAP)
• Immunogenicity and Protective Efficacy of Psoralen-Inactivated SARS-CoV-2 Vaccine in Nonhuman Primates
  Sanders et al., Vaccines (2024) 
  Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
• A multiantigenic Orf virus-based vaccine efficiently protects hamsters and nonhuman primates against SARS-CoV-2
  Reguzova et al., NPJ Vaccines (2024) - PMID: 39414789
  Products used: PepMix™ SARS-CoV-2 (NCAP), PepMix™ SARS-CoV-2 (Spike Glycoprotein)
• Cellular and humoral response to SARS-CoV-2 vaccine BNT162b2 in adults with Chronic Kidney Disease G4/5.
  Rosdahl et al., New Microbes & New Infections (2024) - PMID: 39282145
  Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
• MVA-based vaccine candidates expressing SARS-CoV-2 prefusion-stabilized spike proteins of the Wuhan, Beta or Omicron BA. 1 variants protect transgenic K18-hACE2 mice against Omicron infection and elicit robust and broad specific humoral and cellular immune responses
  Pérez et al., Frontiers in Immunology (2024) - PMID: 39267752
  Product used: PepMix™ SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron)
• SARS-CoV-2 spike-specific nasal-resident CD49a+CD8+ memory T cells exert immediate effector functions with enhanced IFN-γ production
  Rha et al., Nature Communications (2024) - PMID: 39333516
  Product used: PepMix™ SARS-CoV-2 (NCAP)
• Variant-proof high affinity ACE2 antagonist limits SARS-CoV-2 replication in upper and lower airways
  Gagne et al., Nature Communications (2024) - PMID: 39134521
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2) 
• Mucosal adenovirus vaccine boosting elicits IgA and durably prevents XBB.1.16 infection in nonhuman primates
  Gagne et al., Nature Immunology (2024) - PMID: 39227514
  Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2), PepMix™ SARS-CoV-2 (NCAP)
• Endurance Exercise Does Not Exacerbate Cardiac Inflammation in BALB/c Mice Following mRNA COVID-19 Vaccination
  Eens et al., Vaccines (2024)
  Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
• Asian Flush Gene Variant Enhances Cellular Immunogenicity of COVID‐19 Vaccine: Prospective Study in the Japanese General Population
  Bogahawaththa et al., Vaccines (2024)
  Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
• Heterologous mRNA/MVA delivering trimeric-RBD as effectivevaccination regimen against SARS-CoV-2: COVARNA Consortium
  Marcos-Villar et al., Emerging Microbes & Infections
  Product used: PepMix™ SARS-CoV-2 (S-RBD)
• Interleukin‐2‐mediated CD4 T‐cell activation correlates highly with effective serological and T‐cell responses to SARS‐CoV‐2 vaccination in people living with HIV
  Gupta et al., Journal of Medical Virology (2024) - PMID: 39056205
  Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
• Cytokine profile of anti-spike CD4+ T cells predicts humoral and CD8+ T cell responses after anti-SARS-CoV-2 mRNA vaccination
  Benhamouda et al., iScience (2024)
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2) 
• Repeated COVID-19 Vaccination Drives Memory T- and B-cell Responses in Kidney Transplant Recipients: Results From a Multicenter Randomized Controlled Trial
  Malahe et al., Transplantation (2024) 
  Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2) 
• Kinetics of pro- and anti-infammatory spike-specifc cellular immune responses in long-term care facility residents after COVID-19 mRNA primary and booster vaccination: a prospective longitudinal study in Japan
  Kagugawa et al., Immunity and Ageing (2024) - PMID: 38909235
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• Strategies to determine positive anti-SARS-CoV-2 memory T lymphocyte response during the evolution of an epidemic
  Nel et al, Journal of Immunological Models (2024)
  Products used: PepMix SARS-CoV-2 (NCAP), PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2) 
• Switching disease-modifying therapies from sphingosine-1-phosphate receptor modulators to natalizumab or dimethyl fumarate restores immune responses after SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis
  Kanakura et al., Clinical Neurology and Neurosurgery (2024) - PMID: 38901377
  Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
• Intranasal SARS-CoV-2 Omicron variant vaccines elicit humoral and cellular mucosal immunity in female mice
  Slamaning et al., EBioMedicine (2024) - PMID: 38848648
  Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein), PepMix™ SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron) 
• SARS-CoV-2-specific immune responses converge in kidney disease patients and controls with hybrid immunity
  Aguilar-Bretones et al., Vaccines (2024)
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• Imbalance of SARS-CoV-2-specific CCR6+ and CXCR3+ CD4+ T cells and IFN-γ + CD8+ T cells in patients with Long-COVID
  Martínez-Fleta et al., Clinical Immunology (2024) 
  Products used: PepMix SARS-CoV-2 (NCAP), PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2) 
• Optimizing SARS-CoV-2 vaccine responses in kidney transplant recipients: an urgent need
  Cheng et al., Microbiology Spectrum (2024) - PMID: 38747636
  Products used: PepMix SARS-CoV-2 (Spike B.1.617.2 / Delta), SARS-CoV-2 (Spike B.1.1.529 / BA.2 / Omicron) 
• Modulation of innate immune response to mRNA vaccination after SARS-CoV-2 infection or sequential vaccination in humans
  Hellgren et al., JCI Insight (2024)
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• Intranasal vaccination with an NDVvectored SARS-CoV-2 vaccine protects against Delta and Omicron challenges
  Warner et al., Vaccines (2024) - PMID: 38782986
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein) 
• Kinetics of pro- and anti-inflammatory spike-specific T-cell responses in long-term care facility residents after COVID-19 mRNA primary and booster vaccination: A prospective longitudinal study in Japan
  Kakugawa et al., Immunity & Ageing (2024)
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein) 
• Nasal vaccination of triple-RBD scaffold protein with flagellin elicits long-term protection against SARS-CoV-2 variants including JN.1
  Li et al., Signal Transduction and Targeted Therapy (2024) - PMID: 38678055
  Product used: PepMix SARS-CoV-2 (S-RBD)
• COVID-19 vaccination induces distinct T-cell responses in pediatric solid organ transplant recipients and immunocompetent children
  Roznik et al., Vaccines (2024) 
  Products used: PepMix SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (Spike B.1.1.529 / BA.4 & BA.5 / Omicron)
• Innate Responses to the Former COVID-19 Vaccine Candidate CVnCoV and Their Relation to Reactogenicity and Adaptive Immunogenicity
  Wolz et al., Vaccines (2024) 
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• From Vaccination to Infection: Mechanistic Studies of Immune Responses to SARS-COV-2
  Lenart, Dissertation (2024) 
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• Immunogenicity and efficacy of VLA2001 vaccine against SARS-CoV-2 infection in male cynomolgus macaques
  Galhaut et al., Communications Medicine (2024) - PMID: 38570605
  Products used: PepMix SARS-CoV-2 (S-RBD),  SARS-CoV-2 (NCAP)
• Evaluation of T Cell Response to SARS-CoV-2 in Kidney Transplant Recipients Receiving Monoclonal Antibody Prophylaxis and the Utility of a Bivalent mRNA Vaccine Booster Dose
  Bertrand et al., Microorganisms (2024) 
  Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2), SARS-CoV-2 (NCAP), SARS-CoV-2 (NS7A), SARS-CoV-2 (VEMP), SARS-CoV-2 (VME1), SARS-CoV-2 (Nsp3), CEFX Ultra SuperStim Pool
• Carrier-free mRNA vaccine induces robust immunity against SARS-CoV-2 in mice and non-human primates without systemic reactogenicity
  Abbasi et al., Molecular Therapy (2024) 
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• T cell activation markers CD38 and HLA-DR indicative of non-seroconversion in anti-CD20-treated patients with multiple sclerosis following SARS-CoV-2 mRNA vaccination
  Verstegen et al., Multiple Sclerosis (2024) - PMID: 38548324
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
• Comparable CD8+ T‐cell responses to SARS‐CoV‐2 vaccination in single‐cell transcriptomics of recently allogeneic transplanted patients and healthy individuals
  Tranter et al., Journal of Medical Virology (2024) 
  Product used: CEFX Ultra SuperStim Pool, PepMix SARS-CoV-2 (NCAP), SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2), SARS-CoV-2 AP3A (ORF3a), SARS-CoV-2 NS7A, SARS-CoV-2 NS8, Pan‐SARS-CoV-2 Select, and custom PepMix
• Generation of CRISPR-Cas9-edited Tacrolimus-resistant SARS-CoV-2-specific T-cells for adoptive cell therapy in transplant patients
  Peter, Dissertation (2024)
  Products used: PepMix HCMVA (pp65), SARS-CoV-2 peptide pools (NCAP, Spike S1, Spike S2, VEMP, VME1, AP3a, NS6, NS7a, NS7b, NS8, ORF9b, ORF10, Y14)
• Development and Characterization of a Novel DC-Targeting Universal Influenza Vaccine
  Olukitibi et al., Dissertation (2024) 
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1)
• Single MVA-SARS-2-ST/N Vaccination Rapidly Protects K18-hACE2 Mice against a Lethal SARS-CoV-2 Challenge Infection
  Clever et al., Viruses (2024) 
  Product used: PepMix SARS-CoV-2 (NCAP), SARS-CoV-2 Antigen Peptide NCAP (LALLLLDRL), Antigen Peptide IFN-gR H-2 Kb (TSYKFESV)
• NFκB and NLRP3/NLRC4 inflammasomes regulate differentiation, activation and functional properties of monocytes in response to distinct SARS-CoV-2 proteins
  Tsukalov et al., Nature Communications (2024) - PMID: 38453949
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1), SARS-CoV-2 (NCAP)
• Comparable safety and non-inferior immunogenicity of the SARS-CoV-2 mRNA vaccine candidate PTX-COVID19-B and BNT162b2 in a phase 2 randomized, observer-blinded study
  Reiter et al., Scientific Reports (2024) - PMID: 38438427
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• Bivalent mRNA COVID vaccines elicit predominantly cross-reactive CD4+ T cell clonotypes
  Sop et al., Cell Reports Medicine (2024) - PMID: 38423018
  Products used: PepMix SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (Spike B.1.1.529 / BA.4 & BA.5 / Omicron)
• Immune responses to SARS-CoV-2 mRNA vaccination in people with idiopathic CD4 lymphopenia
  Rocco et al., Translational and Clinical Immunology (2024) - PMID: 38344971
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• A Gamma-adapted subunit vaccine induces broadly neutralizing antibodies against SARS-CoV-2 variants and protects mice from infection
  Coria et al., Nature Communications (2024) - PMID: 38307851
  Products used: PepMix™ SARS-CoV-2 (S-RBD), PepMix™ SARS-CoV-2 (S-RBD P.1 / Gamma)
• Humoral and Cellular Immune Responses against SARS-CoV-2 after Third Dose BNT162b2 following Double-Dose Vaccination with BNT162b2 versus ChAdOx1 in Patients with Cancer 
  Debie et al., Clinical Cancer Research (2024) - PMID: 36341493
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
• Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial
  Pant et al., Nature Medicine (2024) - PMID: 38195752
  Products used: PepMix SARS-CoV-2 (S-RBD), CEFSX Ultra SuperStim Pool, CEFT Pool,  Pan-CMV Select, HCMVA pp65,  Pan-EBV Select, CEF Pool (standard) 
• MVA-based vaccine candidates encoding the native or prefusion-stabilized SARS-CoV-2 spike reveal differential immunogenicity in humans
  Mayer et al., Vaccines (2024) - PMID: 38278816
  Product used: CEF Pool (extended), PepMix SARS-CoV-2 (Spike Glycoprotein) 
• Low pre-existing endemic human coronavirus (HCoV-NL63)-specific T cell frequencies are associated with impaired SARS-CoV-2-specific T cell responses in people living with HIV
  Ng'uni et al., Frontiers in Immunology (2024)
  Products used: PepMix™ SARS-CoV-2 (Spike B.1.617.2 / Delta), HCoV-NL63 (Spike Glycoprotein), SARS-CoV-2 (Spike B.1.351 / Beta)
• Caveats of chimpanzee ChAdOx1 adenovirus-vectored vaccines to boost anti-SARS-CoV-2 protective immunity in mice
  Cervantes-Torres et al., Applied Microbiology and Biotechnology (2024) - PMID: 38280035
  Product used: PepMix™ SARS-CoV-2 (S-RBD B.1.617.2 / Delta) 
• Comparison of Omicron Breakthrough Infection Versus Monovalent SARS-CoV-2 Intramuscular Booster Reveals Differences in Mucosal and Systemic Humoral Immunity
  Nantel et al., Mucosal Immunology (2024)
  Products used: PepMix™ SARS-CoV-2 (Spike P.1 / Gamma), SARS-CoV-2 (Spike B.1.351 / Beta), SARS-CoV-2 (Spike B.1.617.2 / Delta), SARS-CoV-2 (Spike B.1.1.7 / Alpha), SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron) 
• Expanded specific T cells to hypomutated regions of the SARS-CoV-2 using mRNA electroporated antigen presenting cells.
  Ogando-Rivas et al., Methods and Clinical Development (2024)
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2), SARS-CoV-2 (VME1), SARS-CoV-2 (VEMP), SARS-CoV-2 (NCAP) 
• Enhanced detection of antigen-specific T cells by a multiplexed AIM assay
  Lemieux et al., Cell Rep Methods (2024) - PMID: 38228152
  Products used: PepMix SARS-CoV-2 (Spike Glycoprotein),  HIV-1 (GAG) Ultra, HIV-1 (POL) Ultra,  HIV-1 (ENV) Ultra, HIV-1 (NEF) Ultra, HCMVA (pp65) 
• Three immunizations with Novavax’s protein vaccines increase antibody breadth and provide durable protection from SARSCoV-2
  Lenart et al., Vaccines (2024) - PMID: 38245545
  Products used: PepMix SARS-CoV-2 (Spike Glycoprotein) 
• Surface-modified measles vaccines encoding oligomeric, prefusion-stabilized SARS-CoV-2 spike glycoproteins boost neutralizing antibody responses to Omicron and historical variants, independent of measles seropositivity
  Muñoz-Alía et al., mBio (2024) - PMID: 38193729
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein) 
• CD3-downregulation identifies T-helper-cells with superior functionality and distinct metabolism in SARS-CoV2-vaccination- and recall-antigen-specific immunity
  Sattler et al., JCI Insight (2024)
  Products used: PepMix™ SARS-CoV-2 (Spike B.1.1.7 / Alpha), SARS-CoV-2 Antigen Peptide Spike Fusion (SFIEDLLFNKVTLAD) 
• Humoral and cellular immune responses after COVID-19 vaccination of lung transplant recipients and patients on the waiting list: a 6-month follow-up
  Hoek et al., Frontiers in Immunology (2024)
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein) 
• Protective MVA-ST Vaccination Robustly Activates T Cells and Antibodies in an Aged-Hamster Model for COVID-19
  Clever et al., Vaccines (2024)
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein) 
• A quest for universal anti-SARS-CoV-2 T cell assay: systematic review, meta-analysis, and experimental validation
  Binayke et al., NPJ Vaccines (2024) - PMID: 38167915
  Products used: PepMix SARS-CoV-2 (Spike Glycoprotein), PepMix Pan-SARS-CoV-2 Select

References Archive

• Production, purification and immunogenicity of Gag virus-like particles carrying SARS-CoV-2 components
  Gashti et al., Vaccine (2023) - PMID:  38042697
  Product used: PepMix SARS-CoV-2 (NCAP)
• Interaction dynamics between innate and adaptive immune cells responding to SARSCoV-2 vaccination in non-human primates
  Schramm et al., Nature Communications (2023) - PMID: 38042809
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• Associations of myeloid cells with cellular and humoral responses following vaccinations in patients with neuroimmunological diseases
  Wang et al., Nature Communications (2023) - PMID: 38007484
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein) 
• Impaired Cellular and Antibody immunity after COVID-19 in Chronically Immunosuppressed Transplant Recipients
  Ashokkumar et al., Journal of Surgery and Research (2023)
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB2)
• A Phase I/II Clinical Trial of Intradermal, Controllable Self-Replicating Ribonucleic Acid Vaccine EXG-5003 against SARS-CoV-2
  Koseki et al., Vaccines (2023) 
  Product used: PepMix SARS-CoV-2 (S-RBD) 
• Efectiveness ofVSV vectored SARS‑CoV‑2 spike when administered through intranasal, intramuscular or a combination of both
  Beitari et al., Scientific Reports (2023) - PMID: 38049498
  Products used: PepMix SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
• Cross-regulation of antibody responses against the SARS-CoV-2 Spike protein and commensal microbiota via molecular mimicry
  Bondareva et al., Cell Host & Microbe (2023) - PMID: 37944493
  Product used: PepStar Peptide Microarray Multiwell SARS-CoV-2 Spike glycoprotein wild type + mutations
• Immunogenicity of a silica nanoparticle-based SARS-CoV-2 vaccine in mice
  Barbey et al., European Journal of Pharmaceutics and Biopharmaceutics (2023) - PMID: 37774890
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2) 
• Impaired immune responses and prolonged viral replication in lung allograft recipients infected with SARS‑CoV‑2 in the early phase after transplantation
  Glueck et al., Infection (2023) - PMID: 37922037
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein) 
• Early humoral and cellular responses after bivalent SARS‐CoV‐2 mRNA‐1273.214 vaccination in long‐term care and retirement home residents in Ontario, Canada: An observational cohort study
  Breznik et al., Journal of Medical Virology (2023) - PMID: 37822054
  Product used: PepMix SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron) 
• Humoral and Cellular Immunity Are Significantly Affected in Renal Transplant Recipients, Following Vaccination with BNT162b2
  Fylaktou et al., Vaccines (2023) 
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein) 
• SARS-CoV-2 infection establishes a stable and age-independent CD8+ T cell response against a dominant nucleocapsid epitope using restricted T cell receptors
  Choy et al., Nature Communications (2023) - PMID: 37872153
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1) 
• Revaccination of patients with systemic lupus erythematosus or rheumatoid arthritis without an initial COVID-19 vaccine response elicits seroconversion in half of the patients
  Ammitzbøll et al., Clinical and Experimental Rheumatology (2023) - PMID: 37877429 
• An interferon-integrated mucosal vaccine provides pan-sarbecovirus protection in small animal models
  Yuen et al., Nature Communications (2023) - PMID: 37875475
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein) 
• Dendritic Cell-Mediated Cross-Priming by a Bispecific Neutralizing Antibody Boosts Cytotoxic T Cell Responses and Protects Mice against SARS-CoV-2
  Lázaro-Gorines et al., Advanced Science (2023) 
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein) 
• T regulatory lymphocytes specific for SARS-CoV-2 display increased functional plasticity
  Esparcia-Pinedo et al., Clinical Immunology - PMID: 37827267
  Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2), PepMix HCMVA (pp65) 
• Immune Profile Determines Response to Vaccination against COVID-19 in Kidney Transplant Recipients
  Stai et al., Vaccines (2023) - PMID: 37896986
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein) 
• Cytokine profile of anti-spike CD4+T cells predicts humoral and CD8+T cell responses after anti-SARSCoV-2 mRNA vaccination
  Tartour et al., Research Square (2023) 
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2) 
• An RNA-Scaffold Protein Subunit Vaccine for Nasal Immunization
  Lam et al., Vaccines (2023) - PMID: 37896953
  Product used: PepMix SARS-CoV-2 (S-RBD) 
• Selection of cross-reactive T cells by commensal and food-derived yeasts drives cytotoxic TH1 cell responses in Crohn’s disease
  Martini et al., Nature Medicine (2023) - PMID: 37749331
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein) 
• Enhanced Omicron subvariant cross-neutralization efficacy of a SARS-CoV-2 BA.4/5 mRNA vaccine encoding a noncleaved, nonfusogenic spike antigen
  Oh et al., Research Square (2023) 
  Product used: PepMix SARS-CoV-2 (Spike B.1.1.529 / BA.4 & BA.5 / Omicron) 
• Spontaneous HIV expression during suppressive ART is associated with the magnitude and function of HIVspecific CD4+ and CD8+ T cells
  Dubé et al., Cell Hosts Microbe (2023) - PMID: 37708853
  Products used: PepMix SARS-CoV-2 (Spike Glycoprotein) 
• Responses of patients with cancer to mRNA vaccines depend on the time interval between vaccination and last treatment
  Donhauser et al., Journal for ImmunoTherapy of Cancer - PMID: 37730271
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein) 
• Long-term humoral and cellular immunity after primary SARS-CoV-2 infection: A 20- month longitudinal study
  Hvidt et al., Research Square (2023) - PMID: 37974069
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein) 
• SARS-CoV-2 variants of concern elicit divergent early immune responses in hACE2 transgenic mice
  Fricke et al., European Journal of Immunology (2023) - PMID: 37609807
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• Enhancing Anti-SARS-CoV-2 Neutralizing Immunity by Genetic Delivery of Enveloped Virus-like Particles Displaying SARS-CoV-2 Spikes
  Yang et al., Vaccines (2023)
  Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
• Intradermal administration of DNA vaccine targeting Omicron SARS‑CoV‑2 via pyro‑drive jet injector provides the prolonged neutralizing antibody production via germinal center reaction
  Hayashi et al., Scientific Reports (2023) - PMID: 37563266
  Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2), SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron)
• Safety and immunogenicity of a SARS-CoV-2 Gamma variant RBD-based protein adjuvanted vaccine used as booster in healthy adults
  Pasquevich et al., Nature Communications (2023)
   Product used: PepMix SARS-CoV-2 (S-RBD P.1 / Gamma)
• Breadth and Durability of SARS-CoV-2-Specific T Cell Responses following Long-Term Recovery from COVID-19
  Dang et al., Microbiology Spectrum (2023) - PMID: 37428088
  Products used: PepMix SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (NCAP), SARS-CoV-2 (VEMP), SARS-CoV-2 (VME1), SARS-CoV-2 (ORF10), SARS-CoV-2 (ORF9B) Custom PepMix : SARS-CoV-2 ORF3a, ORF6, ORF7a, ORF7b, ORF8 
• A localizing nanocarrier formulation enables multi-target immune responses to multivalent replicating RNA with limited systemic inflammation
  Kimura et al., Molecular Therapy (2023) - PMID: 37403357
  Product used: PepMix™ SARS-CoV-2 (Spike B.1.351 / Beta)
• Immunological imprinting of humoral immunity to SARS-CoV-2 in children
  Dowell et al., Nature Communications - PMID: 37386081
  Product used: PepMix™ SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron) & Influenza A (MP1 (H3N2)) 
• Adjuvant lipidoid-substituted lipid nanoparticles augment the immunogenicity of SARS-CoV-2 mRNA vaccines
  Han et al., Nature Nanotechnology (2023) - PMID: 37365276
  Products used: PepMix™ SARS-CoV-2 (S-RBD) 
• Characterization of T cell responses to SARS-CoV-2 following infection and vaccination
  Law, Dissertation (2023)
  Products used: PepMix™SARS-CoV-2 (VME1), SARS-CoV-2 (VEMP), SARS-CoV-2 (NCAP) & SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2) 
• Oligosymptomatic long-term carriers of SARS-CoV-2 display impaired innate resistance but increased high-affinity anti-Spike antibodies
  Montes-Cobos et al., iScience (2023)
   Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
• Third and Fourth Vaccine Doses Broaden and Prolong Immunity to SARSCoV-2 in Adult Patients with Immune-Mediated Inammatory Diseases
  Cheung et al., Journal of Immunology (2023) - PMID: 37326480
  Product used: PepMix SARS-CoV-2 (Spike B.1.1.529 / BA.4 & BA.5 / Omicron) 
• T-Cell-Dominated Immune Response Resolves Protracted SARS-CoV-2 Infection in the Absence of Neutralizing Antibodies in an Immunocompromised Individual
  Bunse et al., Microorganisms (2023) - PMID: 37375064
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
• High efficacy of VLA2001 vaccine against SARSCoV-2 infection in non-human primates
  Le Grand et al., Research Square (2023)
  Products used: PepMix™ SARS-CoV-2 (S-RBD) & SARS-CoV-2 (NCAP) 
• A novel multi-antigenic parapoxvirus-based vaccine demonstrates efficacy in protecting hamsters and non-human primates against SARS-CoV-2 challenge
  Reguzova et al., Research Square et al., (2023)
   Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) & SARS-CoV-2 (NCAP) 
• The Influence of Adjuvant Type on the Immunogenicity of RBD/N Cocktail Antigens as a Vaccine Candidate against SARS-CoV-2 Virus
  Brzuska et al., Microbiology Spectrum (2023) - PMID: 37199661
  Product used: PepMix™ SARS-CoV-2 (S-RBD)
• Specific immune response to mRNA vaccines against COVID-19 in patients receiving allogeneic stem cell transplantation for myeloid malignancy was altered by immunosuppressive therapy
  Macková et al., Leukemia Research (2023) - PMID: 37216792
  Product used: PepMix™ SARS-CoV-2 (NCAP)
• Impact of age and comorbidities on SARS-CoV-2 vaccine-induced T cell immunity
  Dietz et al., Communications Medicine (2023) - PMID: 37095240
  Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) 
• ESCRT recruitment to SARS-CoV-2 spike induces virus-like particles that improve mRNA vaccines
  Hoffmann et al., Cell (2023) - PMID: 37146611
  Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) 
• COVID-19 relapse associated with SARS-CoV-2 evasion from CD4+ T-cell recognition in an agammaglobulinemia patient
  Morita et al., iScience (2023) - PMID: 37124420
  Products used: 27 structural and non-structural PepMix SARS-CoV-2 proteins 
• Omicron BA.4/5 neutralization and T-cell responses in organ transplant recipients after Booster mrna vaccine: a Multicenter Cohort Study
  Ferreira et al., Clinical Infectious Diseases (2023) - PMID: 36975097
  Product used: PepMix SARS-CoV-2 (Spike B.1.1.529 / BA.4 & BA.5 / Omicron) 
• Cytotoxic T Cells Targeting Spike Glycoprotein Are Associated with Hybrid Immunity to SARS-CoV-2
  Phan et al., Journal of Immunology (2023) - PMID: 36961450
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) & SARS-CoV-2 (NCAP) 
• Humoral and cellular immunity to SARS-CoV-2 after vaccination with mRNA vaccines in PLWH with discordant immune response. Influence on the vaccine administered
  López-Cortés et al., Frontiers in Immunology (2023) - PMID: 37006309
  Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) 
• SARS-CoV-2 spike-ferritin-nanoparticle adjuvanted with ALFQ induces long-lived plasma cells and cross-neutralizing antibodies
  Shrivastava et al., Vaccines (2023) - PMID: 36934088
  Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) 
• Immunogenicity of COVID-eVax Delivered by Electroporation Is Moderately Impacted by Temperature and Molecular Isoforms
  D'Alessio et al., Vaccines (2023) - PMID: 36992261
  Product used: PepMix™ SARS-CoV-2 (S-RBD)
• Incorporation of SARS-CoV-2 spike NTD to RBD Protein Vaccine Improves Immunity Against Viral Variants
  Montgomerie et al., IScience (2023)
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein) 
• Pyrimidine de novo synthesis inhibition selectively blocks effector but not memory T cell development
  Scherer et al., Nature Immunology (2023)
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein) 
• Carbohydrate fatty acid monosulphate: oil-in-water adjuvant enhances SARS-CoV-2 RBD nanoparticle-induced immunogenicity and protection in mice
  Nanishi et al., Vaccines (2023)
  Product used: PepMix SARS-CoV-2 (S-RBD) 
• Efficacy of an unmodified bivalent mRNA vaccine against SARS-CoV-2 variants in female small animal models
  Corleis et al., Nature Communications (2023)
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• Linear epitope mapping of the humoral response against SARS‑CoV‑2 in two independent African cohorts
  Vigan-Womas et al., Scientific Reports (2023)
  Product used: custom PepStar & PepSpots Peptides on Cellulose 
• Immunogenicity and safety of Biological E’s CORBEVAX™ vaccine as a heterologous booster dose in adult volunteers previously vaccinated with two doses of either COVISHIELD™ or COVAXIN: A Prospective double-blind randomised hase III clinical study
  Thuluva et al., MedRxiv (2023)
  Product used: PepMix SARS-CoV-2 (S-RBD)
• Assessment of Immunogenicity and Efficacy of CV0501 mRNA-based Omicron COVID-19 Vaccination in Small Animal Models
  Roth et al., BioRxiv (2023)
  Product used: PepMix SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron) 
• Safety, tolerability, and immunogenicity of a new SARS-CoV-2 recombinant Gamma variant RBD-based protein adjuvanted vaccine, used as heterologous booster in healthy adults: a Phase 1 interim report
  Pasquevich et al., MedRxiv (2023)
  Product used: PepMix SARS-CoV-2 (S-RBD P.1 / Gamma)
• An inactivated SARS-CoV-2 vaccine induced cross-neutralising persisting antibodies and protected upon challenge in small animals
  Offersgaard et al., iScience (2023)
  Products used: PepMix SARS-CoV-2 (S-MUT), SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (S-RBD), SARS-CoV-2 (NCAP), SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2),
• Diminished responses to mRNA-based SARS-CoV-2 vaccines in individuals with rheumatoid arthritis on immune modifying therapies
  Klebanoff et al., MedRxiv (2023)
  Products used: PepMix CEFX Ultra Superstim Pool & SARS-CoV-2 (Spike Glycoprotein)
• A linear DNA encoding the SARS-CoV-2 receptor binding domain elicits potent immune response and neutralizing antibodies in domestic cats
  Conforti et al., Molecular Therapy (2023)
  Product used: PepMix SARS-CoV-2 (S-RBD)
• The HDAC inhibitor zabadinostat is a systemic regulator of adaptive immunity
  Liu et al., Communications Biology (2023)
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• SARS-CoV-2 Omicron BA.4/BA.5 Mutations in Spike Leading to T Cell Escape in Recently Vaccinated Individuals
  Emmelot et al., Viruses (2023)
  Products used: custom PepMix

• SARS-CoV-2 Spike-specific IFN-gamma T-cell Response After COVID-19 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant
  Imhof et al., Infectious Disease (2022)
  Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
• Efficacy of mucosal vaccination using a protozoan parasite as a vehicle for antigen delivery: IgG and neutralizing response after rectal administration of LeCoVax-2, a candidate vaccine against COVID-19
  Epis et al., Pharmacological Research (2022) - PMID: 36336215
• Reduced humoral but stable cellular SARS-CoV-2-specific immunity in liver transplant recipients in the first year after COVID-19
  Kirchner et al., PLoS One (2022) - PMID: 36322587
• Immunodominant Linear B-Cell Epitopes of SARS-CoV-2 Spike, Identified by Sera from K18-hACE2 Mice Infected with the WT or Variant Viruses
  Levy et al., Vaccines (2022) - PMID: 34650130
• Immunization with 674e685 fragment of SARS-Cov-2 spike protein induces neuroinflammation and impairs episodic memory of mice
  Lykhmus et al., Biochemical and Biophysical Research Communications (2022)
• Treatment of Long COVID with nirmatrelvir/ritonavir and tocilizumab in a patient with rheumatoid arthritis and SARS-CoV-2 antigen persistence: a case report
  Visvabharathy et al., Research Square (2022) 
• SARS-CoV-2 mRNA vaccinations fail to elicit humoral and cellular immune responses in patients with multiple sclerosis receiving fingolimod
  Meyer-Arndt et al., J Neurol Neuroscurg Psychiatry (2022) - PMID: 35835468
• A single intranasal dose of human parainfluenza virus type 3-vectored vaccine induces effective antibody and memory T cell response in the lungs and protects hamsters against SARS-CoV-2
  Ilinykh et al., Vaccines (2022) 
• High‑resolution analysis of long‑term serum antibodies in humans following convalescence of SARS‑CoV‑2 infection
  Facciuolo et al., Scientific Reports (2022)
• SARS-CoV-2 mRNA vaccination fails to elicit humoral and cellular immune responses in multiple sclerosis patients receiving fingolimod
  Meyer-Arndt et al., MedRxiv (2022)
  Products used: PepStar SARS-CoV-2 Spike Glycoprotein Variant Collection (incl. Omicron)
• Brief Research Report: Anti-SARS-CoV-2 Immunity in Long Lasting Responders to Cancer Immunotherapy Through mRNA-Based COVID-19 Vaccination
  Sistere-Oro et al., Frontiers in Immunology (2022) 
• DNA-Vaccine-Induced Immune Response Correlates with Lower Viral SARS-CoV-2 Titers in a Ferret Model
  Compagnone et al., Vaccines (2022) - PMID: 35893826 
• SARS-CoV-2 Vaccine-Induced Antibody and T-Cell Response in SARS-CoV-1 Survivors
  Duan et al., Cell Reports (2022) 
• The long term vaccine-induced anti-SARS-CoV-2 immune response is impaired in quantity and qualityunder TNFα blockade
  Geisen et al., Journal of Medical Virology (2022) - PMID: 35945627
• Secreted heat shock protein gp96-Ig and OX40L-Fc combination vaccine enhances SARS-CoV-2 Spike (S) protein-specific B and T cell immune responses
  Padula et al., Vaccine: X (2022) - PMID: 35936992
  Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SU1 & SU2) 
• Analysis of the Specific Immune Response after the Third Dose of mRNA COVID-19 Vaccines in Organ Transplant Recipients: Possible Spike-S1 Reactive IgA Signature in Protection from SARS-CoV-2 Infection
  Miele et al., Microorganisms (2022)
  Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SU1 & SU2) & SARS-CoV-2 NCAP 
• mRNA booster vaccination protects aged mice against the SARS-CoV-2 Omicron variant
  Nanishi et al., Communications Biology (2022) 
• SARS-CoV-2-specific CD4+ T cell longevity correlates with Th17-like phenotype
  Terahara et al., iScience (2022) - PMID: 35992306
• SARS‑CoV‑2‑reactive IFN‑γ‑producing CD4+ and CD8+T cells in blood do not correlate with clinical severity in unvaccinated critically ill COVID‑19 patients
   Olea et al., Scientific Reports (2022) - PMID: 35995830
  
• Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral response
  Stort et al., Oncoimmunology (2022)
   Product used: PepMix SARS-CoV-2 (Spike Glycoprotein) 
• Humoral and cellular responses to mRNA-based COVID-19 booster vaccinations in patients with solid neoplasms under active treatment
  Su et al., ESMO Open (2022)
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein) 
• Protective Immunity of COVID-19 Vaccination with ChAdOx1 nCoV-19 Following Previous SARS-CoV-2 Infection: A Humoral and Cellular Investigation
  Azamor et al., Viruses (2022) - PMID: 36146723
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein) 
• Antibody and T-cellular response to COVID-19 booster vaccine in SARS-CoV-1 survivors
  Lu et al., Clinical Immunology (2022)
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• Comparison of the Immune Responses to COVID-19 Vaccines in Bangladeshi Population
  Sarker et al., Vaccines (2022)
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein) 
• Comparison between enzyme‐linked immunospot assay and intracellular cytokine flow cytometry assays for the evaluation of T cell response to SARS‐CoV‐2 after symptomatic COVID‐19
  Villemonteix et al., Immunity, Inflammation and Disease (2022)
  Products used: PepMix SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (NCAP) 
• Dual spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 Omicron and Delta variants in preclinical models
  Hajnik et al., Science Translational medicine (2022) - PMID: 36103514
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein) 
• A Recombinant VSV-Based Bivalent Vaccine Effectively Protects against Both SARS-CoV-2 and Influenza A Virus Infection
  Ao et al., Journal of Virology (2022) - PMID: 36069551
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1) 
• SARS-CoV-2 mRNA-vaccine candidate; COReNAPCIN, induces robust humoral and cellular immunity in mice and non-human primates
  Alimohammadi et al., Vaccines (2022) - PMID: 36056015
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• Ablation of CD8+ T cell recognition of an immunodominant epitope in SARS-CoV-2 Omicron variants BA.1, BA.2 and BA.3
  Swaminathan et al., Nature Communications
  Products used: PepMix SARS-CoV-2 (NCAP), SARS-CoV-2 (NS6), SARS-CoV-2 (NS7A), SARS-CoV-2 (NS7B), SARS-CoV-2 (NS8), SARS-CoV-2 (ORF9B), SARS-CoV-2 (ORF10), SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (VEMP), SARS-CoV-2 (VME1), SARS-CoV-2 (Y14) 
• Accumulation of mutations in antibody and CD8 T cell epitopes in a B cell depleted lymphoma patient with chronic SARS-CoV-2 infection
  Khatamzas et al., Nature Communication (2022)
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein) 
• Evidence of premature lymphocyte aging in people with low anti-spike antibody levels after BNT162b2 vaccination
  Huang et al., iScience (2022)
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• NVX-CoV2373-induced cellular and humoral immunity towards parental SARS-CoV-2 and VOCs compared to BNT162b2 and mRNA-1273-regimens
  Hielscher et al., Journal of Clinical Virology (2022) - PMID: 36279695
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein) 
• Immune Response after the Fourth Dose of SARS-CoV-2 mRNA Vaccine Compared to Natural Infection in Three Doses’ Vaccinated Solid Organ Transplant Recipients
  Busà et al., Vaccines (2022) - PMID: 36298854
  Products used: PepMix SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (NCAP) and CEFX Ultra SuperStim Pool 
• Proinflammatory Innate Cytokines and Distinct Metabolomic Signatures Shape the T Cell Response in Active COVID-19
  Binayke et al., Vaccines (2022) - PMID: 36298628
  Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2) 
• Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose
  Belik et al., Research Square (2022)
  Products used: PepMix SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron), and SARS-CoV-2 (Spike B.1.1.529 / BA.2 / Omicron)
• Artificial Cell Membrane Polymersome-Based Intranasal Beta Spike Formulation as a Second Generation Covid-19 Vaccine
  Lam et al., ACS Nano (2022)
  Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2) 
• Signs of immunosenescence correlate with poor outcome of mRNA COVID-19 vaccination in older adults
  Palacios-Pedrero et al., Nature Aging (2022)
  Product used: PepMix SARS-CoV-2 (NCAP)
• Humoral and Cellular Responses to a Delayed Fourth SARS-CoV-2 mRNA-Based Vaccine in Weak Responders to 3 Doses Kidney Transplant Recipients
  Del Bello et al., Vaccines (2022) - PMID: 36146517
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2) 
• A third dose of the unmodified COVID-19 mRNA vaccine CVnCoV enhances quality and quantity of immune responses
  Lenart et al., Molecular Therapy (2022)
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein) 
• A Tale Of T ale Of Two Transgenes: Aa ansgenes: Aav-Dystr v-Dystrophin And Aa ophin And Aav-Spike Reveal Common Themes For Gene Therapy And Vaccines
  Greer, Dissertation (2022)
  Products used: PepMix SARS-CoV-2 (Spike Glycoprotein) and SARS-CoV-2 (Spike B.1.1.7 / Alpha) 
• Immunogenicity of SARS-CoV-2 spike antigens derived from Beta & Delta variants of concern
  Akache et al., Vaccines (2022)
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• Analysis of the humoral and cellular response after the third COVID-19 vaccination in patients with autoimmune hepatitis
  Hartl et al., Liver International (2022) - PMID: 35840342
• Respiratory mucosal immunity against SARS-CoV-2 following mRNA vaccination
  Tang et al., Science Immunology (2022) - PMID: 35857583
• Robust SARS-COV-2-specific T-cell immune memory persists long-term in immunocompetent individuals post BNT162b2 double shot
  Papadopoulou et al., Heliyon (2022) - PMID: 35815135
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein) 
• A novel SARS-CoV-2 subunit vaccine engineered on an immune-activating platform technology
  Quinlan et al., Human Vaccines & Immunotherapeutics (2022) - PMID: 35801956
  Product used: PepMix SARS-CoV-2 (Spike-RBD) 
• Safety and immunogenicity of intramuscular, single- dose V590 (rVSV-SARS-CoV-2 Vaccine) in healthy adults: Results from a phase 1 randomised, double- blind, placebo-controlled, dose-ranging trial
  Robbins et al., The Lancet (2022)
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein) 
• Longitudinal T Cell Responses against Ancestral, Delta, and Omicron SARS-CoV-2 Variants determined by Rapid Cytokine Release Assay in Whole Blood
  Oliver et al., Immunohorizons (2022) - PMID: 35750357
  Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SU1 & SU2), SARS-CoV-2 (Spike B.1.617/Delta),  SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron)
  
• Long-Lived Immunity in SARS-CoV-2-Recovered Children and Its Neutralizing Capacity Against Omicron
  Sieber et al., Frontiers in Immunology (2022) - PMID: 35663948
  Product used: PepMix SARS-CoV-2 (VME1), SARS-CoV-2 (VEMP), SARS-CoV-2 (NCAP),  SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron) 
• T-cell proliferation assay for the detection of SARS-CoV-2-specific T-cells
  Chu et al., Clinical Chimica Acta (2022) - PMID: 35690083
  Products used: PepMix SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (NCAP), SARS-CoV-2 (VME1) 
• A DNA vaccine candidate delivered by an electroacupuncture machine provides protective immunity against SARS-CoV-2 infection
  Tzeng et al., Vaccines (2022) 
• Chimeric Virus-like Particle-Based COVID-19 Vaccine Confers Strong Protection against SARS-CoV-2 Viremia in K18-hACE2 Mice
  Kaewborisuth et al., Vaccines (2022) 
• SARS-CoV-2 OmicronBA.1 variant breakthrough infections in nursing home residentsafter an homologousthird dose of the Comirnaty® COVID-19 vaccine: Looking for correlates of protection
  Torres et al., Journal of Medical Virology (2022) 
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
• Functional Analysis of Human and Feline Coronavirus Cross-Reactive Antibodies Directed Against the SARS-CoV-2 Fusion Peptide
  Vanderheijden et al., Frontiers in Immunology (2022) - PMID: 35069571
• Durable immunogenicity, adaptation to emerging variants and low dose efficacy of AAV-based COVID19 platform in macaques
  Zabaleta et al., Molecular Therapy (2022)
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
• Enhanced Humoral Immune Response After COVID-19 Vaccination in Elderly Kidney Transplant Recipients on Everolimus Versus Mycophenolate Mofetil–containing Immunosuppressive Regimens
  de Boer et al., Translantation (2022) - PMID: 35546527
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
• SARS-CoV2 wild type and mutant specific humoral and T cell immunity is superior after vaccination than after natural infection
  Richardson et al., PLoS One (2022) - PMID: 35468147
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (Spike B.1.1.7 / Alpha), SARS-CoV-2 (Spike B.1.351 / Beta), SARS-CoV-2 (Spike P.1 / Gamma), SARS-CoV-2 (Spike B.1.617.2 / Delta)
• Two DNA vaccines protect against severe disease and pathology due to SARS-CoV-2 in Syrian hamsters
  Babuadze et al., NPJ Vaccines (2022) - PMID: 35474311
  Product used: PepMix™ SARS-CoV (Spike Glycoprotein)
• Transcriptomic analysis reveals optimal cytokine combinations for SARS-CoV-2 Specific T cell therapy products
  Durkee-Shock et al., Molecular Therapy: Methods & Clinical Development (2022)
• Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod
  Cabeza et al., Neurology: Neuroimmunology & Neuroinflammation - PMID: 35523569
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
• Children and Adults With Mild COVID-19: Dynamics of the Memory T Cell Response up to 10 Months
  Kaaijk et al., Frontiers in Immunology (2022)
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (NCAP), HCoV-OC43 (Spike Glycoprotein)
• Strong peak immunogenicity but rapid antibody waning following third vaccine dose in elderly residents of care homes
  Tut et al., Research Square (2022)
  Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
• Discordant antibody and T cell responses to the SARS-CoV-2 Omicron variant in COVID-19 mRNA vaccine recipient
  Woldemeskel et al., Clinical Infectious Diseases (2022) - PMID: 35438751
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) & SARS-CoV-2 (S-RBD B.1.1.529 / Omicron)
• USA SARS-CoV-2 Epsilon Variant: Though Highly Transmissible has an Adjusted Muted Host T-Cell Response
  Plummer et al., Clinical Infectious Diseases (2022) - PMID: 35438777
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) & SARS-CoV-2 (Spike B.1.429 / Epsilon)
• mRNA booster vaccination protects extremely aged mice against the SARS-CoV-2 Omicron variant
  Dowling et al., Research Square (2022)
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) & SARS-CoV-2 (S-RBD B.1.1.529 / Omicron)
• Viral Evolution and Immunology of SARS-CoV-2 in a Persistent Infection after Treatment with Rituximab
  van der Moerden et al., Viruses (2022)
• Dynamics of SARS-CoV-2-Spike-reactive antibody and T-cell responses in chronic kidney disease patients within three months after COVID-19 full vaccination
  Panizo et al., Clinical Kidney Journal (2022)
  Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
• Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): a single blind, randomized, non-inferiority trial
  Pannus et al., MedRxiv (2022)
• Temporal changes in T cell subsets and expansion of cytotoxic CD4+ T cells in the lungs in severe COVID-19
  Kaneko et al., Clinical Immunology (2022) - PMID: 35364330
  
• T cell response against SARS-CoV-2 persists after one year in patients surviving severe COVID-19
  Venet et al., EBioMedicine (2022) - PMID: 35349827
  
• CD4+ T Cell Dysfunction in Severe COVID-19 Disease is TNFalpha/TNFRI-Dependent
  Popescu et al., American Journal of Respiratory Critical Care Medicine - PMID: 35348444
  
• The Quality of Anti-SARS-CoV-2 T Cell Responses Predicts the Neutralizing Antibody Titer in Convalescent Plasma Donors
  Kroemer et al., Front Public Health (2022) - PMID: 35372242
  
• High antibody and reduced cellular response in children up to one year after SARS-CoV-2 infection
  Jacobsen et al., Research Square (2022)
  
• Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study
  Lim et al., Nature Cancer (2022) - PMID : 35332334
  
• Self-amplifying mRNA SARS-CoV-2 vaccines raise cross-reactive immune response to variants and prevent infection in animal models
  Palladino et al., Methods and Clinical Development (2022)
  
• Evolution of Humoral and Cellular Immunity in Two COVID-19 Breakthrough Infections After BNT162b2 Vaccine
  Gallais et al., Frontiers in Immunology (2022) - PMID: 35281046
  
• SARS‐CoV‐2 vaccination response in patients with autoimmune hepatitis and autoimmune cholestatic liver disease
  Duengelhoef et al., United European Gastroenterol Journal (2022) - PMID: 35289983
  
• Novel T cell interferon gamma release assay (IGRA) using spike recombinant protein for COVID19 vaccine response and Nucleocapsid for SARS-Cov2 response
  Renaudineau et al., Clinical Immunology (2022) - PMID: n.a.
  
• Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination
  Sheng et al., Journal of the Formosan Medical Association (2022) - PMID: 35305895
  
• Modular capsid decoration boosts adenovirus vaccine-induced humoral and cellular immunity against SARS-CoV-2
  Dicks et al., BioRxiv (2022)
• SARS-CoV- 2 (COVID- 19)-specific T cell and B cell responses in convalescent rheumatoid arthritis: Monozygotic twins pair case observation
  Arruda et al., Immunology (2022) - PMID: 35212005
  Products used: PepMix™ SARS-CoV-2 (NCAP) & SARS-CoV-2 (Spike Glycoprotein)
• Humoral and Cellular Immune Responses of Solid Organ Transplant Patients on Belatacept to Three Doses of mRNA-Based Anti-SARS-CoV-2 Vaccine
  Abravanel et al., Vaccines (2022)
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
• Three-month follow-up of heterologous vs homologous third vaccination in kidney transplant recipients
  Heinzel et al., MedRxiv (2022)
  
• Performance comparison of a fow cytometry immunoassay for intracellular cytokine staining and the QuantiFERON® SARS-CoV-2test for detection and quantifcation of SARS-CoV-2-Spike-reactiveIFN-γ-producing T cells after COVID-19 vaccination
  Tormo et al., European Journal of Clinical Microbiology & Infectious Diseases (2022) - PMID: 35165804
• SARS-CoV-2-specific T cells generated for adoptive immunotherapy are capable of recognizing multiple SARS-CoV-2 variant
  Panikkar et al., Pathogens (2022) - PMID: 35157735
• T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all prior infected and vaccinated individuals
  Vivek Naranbhai et al., MedRxiv (2022) - PMID: 35018386
• Innate and adaptive immune defects associated with lower SARS-CoV-2 BNT162b2 mRNA vaccine response in elderly people
  Joana Vitallé et al., medRxiv (2022) - PMID: n.a.
• Temporary hold of mycophenolate boosts SARS-CoV-2 vaccination-specific humoral and cellular immunity in kidney transplant recipients
  Eva Schrezenmeier et al., MedRxiv (2022) 
• Dynamics of spike-and nucleocapsid specific immunity during long-term follow-up and vaccination of SARS-CoV-2 convalescents
  Nina Koerber et al., Nature Communications (2022)
• Persistent T-Cell Reactivity in a Seronegative Patient after SARS-CoV-2 Infection and One Vaccination
  Nico Andreas et al., Vaccines (2022)
• Development of an effective immune response in adults with Down Syndrome 2 after SARS-CoV-2 vaccination
  Laura Esparcia-Pinedo et al., MedRxiv (2022) 
• Antibody and T cell responses to SARS-CoV-2 mRNA vaccines during maintenance therapy for immune-mediated inflammatory diseases
  Dayam et al., MedRxiv (2022)
• Infection or a third dose of mRNA vaccine elicit neutralizing antibody responses against SARS-CoV-2 in kidney transplant recipients
  Charmetant et al., Science Translational Medicine (2022) - PMID: 35103481
• Concordance of B and T cell responses to SARS-CoV-2 infection, irrespective of symptoms suggestive of COVID-19
  Österdahl et al., MedRxiv (2022) 
• Full efficacy and long-term immunogenicity induced by the SARS-CoV-2 vaccine candidate MVA-CoV2-S in mice
  Lázaro-Frías et al., Vaccines (2022)
• mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits comparable B cell expansion, neutralizing antibodies and protection against Omicron
  Gagne et al., BioRxiv (2022)
• Effectiveness and durability of the mRNA vaccine-induced SARSCoV-2-specific humoral and cellular immunity in severe asthma patients on biological therapy
  Prodrazil et al., MedRxiv (2022)
• Limited Recognition of Highly Conserved Regions of SARS-CoV-2
  Swaminathan et al., Microbiology Spectrum (2022) - PMID: 35196796
  
• Assessment of humora land cellular immune responses to SARSCoV-2 vaccination (BNT162b2) inimmunocompromised renal allograft recipients
  Zhang et al., Transplant Infectious Diseases (2022)
  
• Tacrolimus-resistant SARS-CoV-2-specific T-cell products to prevent and treat severe COVID-19 in immunosuppressed patients
  Peter et al., Molecular Therapy (2022)
  
• BNT162b2 Vaccine Induces Neutralizing Antibodies and Poly-Specific T Cells in Humans
  Ugur Sahin et al., Nature (2021)
• Cross-Reactive CD4+ T Cells Enhance SARS-CoV-2 Immune Responses Upon Infection and Vaccination
  Loyal et al, Science (2021)
• Protection Against SARS-CoV-2 Beta Variant in mRNA-1273 Vaccine–Boosted Nonhuman Primates
  Kizzmekia S. Corbett et al., Science, (2021)
• Children Develop Strong and Sustained Cross-Reactive Immune Responses Against Spike Protein Following SARS-CoV-2 Infection, With Enhanced Recognition of Variants of Concern
  Alexander C. Dowell et.al., medRxiv (2021)
• Comorbid illnesses are associated with altered adaptive immune responses to SARS-CoV-2
  Krystle K.Q. Yu et.al., JCI Insight (2021) - PMID: 33621211
• Targeting SARS-CoV-2 Receptor-Binding Domain to Cells Expressing CD40 Improves Protection to Infection in Convalescent Macaques
  Romain Marlin et.al., Nature Communications (2021)
• Longitudinal Analysis of Human Memory T-Cell Response according to the Severity of Illness up to 8 Months after SARS-CoV-2 Infection
  Chang Kyung Kang et.al., The Journal of Infectious Diseases (2021) - PMID: 33755725
• Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection
  Jianmin Zuo et.al., Nature (2021) - PMID: 33674800
• SARS-CoV-2 Spike Protein Arrested In The Closed State Induces Potent Neutralizing Responses
  George W. Carnell et.al., bioRxiv (2021)
• First Report Demonstrating The Safety And Immunogenicity Of The SARS-COV-2 BNT162b1 mRNA Vaccine In Younger And Older Chinese Adults: A Randomized, Placebo-Controlled, Observer-Blind Phase I Study
  Fengcai Zhu et.al., Research Square (2021)
• Poor Anti-SARS-CoV-2 Humoral and T-cell Responses After 2 Injections of mRNA Vaccine in Kidney Transplant Recipients Treated With Belatacept
  Nathalie Chavator et al., Transplantation, (2021)
• SARS-CoV-2 Specific Memory T Cell Epitopes Identified in COVID-19-Recovered Subjects
  Juan Zhao et al., Virus Res, (2021)
• SARS-CoV2 Mutant-Specific T Cells and Neutralizing Antibodies After Vaccination and up to 1 Year After Infection
  Richardson, J.R. et al., ISAR Bioscience, (2021)
• COVID-19 Subunit Vaccine with a Combination of TLR1/2 and TLR3 Agonists Induces Robust and Protective Immunity
  Soo-Kyung Jeong et al., Vaccines, (2021)
• Impairment of CD4+ T and Memory B Cell Responses but Normal Memory CD8+T-Cell Activation on Crohn’s Disease after COVID-19 Vaccination: A Twin Case
  Fabiana Gil-Melgaço et al., Viruses, (2021)
• Weak Immunogenicity of SARS-CoV-2 Vaccine in Patients With Hematologic Malignancies
  Florent Malard et al., Blood Cancer J, (2021)
• CD4+ T Cells of Prostate Cancer Patients Have Decreased Immune Responses to Antigens Derived From SARS-CoV-2 Spike
  Pavla Taborska et al., Front Immunol, (2021)
• T Cell–Mediated Response to SARS-CoV-2 in Liver Transplant Recipients With Prior COVID-19
  Mario Fernández-Ruiz et al., Am J Transplant, (2021)
• Prospective Assessment of SARS-CoV-2 Seroconversion (PASS) Study: an Observational Cohort Study of SARS-CoV-2 Infection and Vaccination in Healthcare Workers
  Jackson, B.M. et al., BMC Infect Dis, (2021)
• Cellular Immunity Predominates Over Humoral Immunity After Homologous and Heterologous mRNA and Vector-Based COVID-19 Vaccine Regimens in Solid Organ Transplant Recipients
  Tina Schmidt et al., Am J Translplant, (2021)
• The Legacy of Maternal SARS-CoV-2 Infection on the Immunology of the Neonate
  Sarah Gee et al., Nat Immunol, (2021)
• A Single-Cycle Influenza A Virus-Based SARS-CoV-2 Vaccine Elicits Potent Immune Responses in a Mouse Model
  Surapong Koonpaew et al., Vaccines, (2021)
• Impact of Multiple Sclerosis Disease-Modifying Therapies on SARS-CoV-2 Vaccine-Induced Antibody and T Cell Immunity
  Sabatino, J.J. et al., MedRxiv, (2021)
• Complete Protection of Nasal and Lung Airways Against SARS-CoV-2 Challenge by Antibody Plus Th1 Dominant N- and S-Specific T-Cell Responses to Subcutaneous Prime and Thermally-Stable Oral Boost Bivalent hAd5 Vaccination in an NHP Study
  Elizabeth Gabitzsch et al., BioRxiv, (2021)
• The Evaluation of Novel Oral Vaccines Based on Self-Amplifying RNA Lipid Nanparticles (saRNA LNPs), saRNA Transfected Lactobacillus Plantarum LNPs, and saRNA Transfected Lactobacillus Plantarum to Neutralize SARS-CoV-2 Variants Alpha and Delta
  Reza Keikha et al., Sci Rep, (2021)
• Single-Dose Intranasal Administration of AdCOVID Elicits Systemic and Mucosal Immunity against SARS-CoV-2 and Fully Protects Mice from Lethal Challenge
  King R.G. et al., Vaccines, (2021)
• T-Cell and Antibody Immunity After COVID-19 mRNA Vaccines in Healthy and Immunocompromised Subjects-An Exploratory Study
  Rakesh Sindhi et al., MedRxiv, (2021)
• SARS-CoV-2-Specific Antibody and T Cell Response Kinetics According to Symptom Severity
  Ji Yeun Kim et al., Am J Trop Med Hyg, (2021)
• Implementation of Adenovirus-Mediated Pulmonary Expression of Human ACE2 in HLA Transgenic Mice Enables Establishment of a COVID-19 Murine Model for Assessment of Immune Responses to SARS-CoV-2 Infection
  Theodor Chitlaru et al., Pathogens, (2021)
• Dynamics of Antibody Response to BNT162b2 Vaccine After Six Months: a Longitudinal Prospective Study
  Naaber, Paul et al., Lancet Reg Health Eur, (2021)
• Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomised, Placebo-Controlled, Phase 1/2 Trial
  Punnee Pitisuttihum et al., MedRxiv, (2021)
• Protracted yet Coordinated Differentiation of Long-Lived SARS-CoV-2-Specific CD8+ T Cells During COVID-19 Convalescence
  Tongcui Ma et al., BioRxiv, (2021)
• SARS-Cov-2 Spike Protein Fragment 674–685 Protects Mitochondria From Releasing Cytochrome c in Response to Apoptogenic Influence
  Olena Kalashnyk et al., Biochem Biophys Res Commun, (2021)
• CD8+PD-L1+CXCR3+ Polyfunctional T Cell Abundances Are Associated With Survival in Critical SARS-CoV-2–Infected Patients
  Lucille Adam et al., JCI Insight, (2021)
• Protective Antibodies Elicited by SARS-CoV-2 Spike Protein Vaccination are Boosted in the Lung After Challenge in Nonhuman Primates
  Joseph R. Francica et al., Sci Transl Med, (2021)
• Profiling SARS-CoV-2 HLA-I Peptidome Reveals T Cell Epitopes From Out-of-Frame ORFs
  Shira Weingarten-Gabbay et al., Cell, (2021)
• A Short Corticosteroid Course Reduces Symptoms and Immunological Alterations Underlying Long-COVID
  Alberto Utrero-Rico et al., Biomedicines, (2021)
• COVID-19 Vaccine mRNA-1273 Elicits a Protective Immune Profile in Mice That is not Associated With Vaccine-Enhanced Disease Upon SARS-CoV-2 Challenge
  DiPiazza, A.T. et al., Immunity, (2021)
• An Enveloped Virus-Like Particle Vaccine Expressing a Stabilized Prefusion form of the SARS-CoV-2 spike Protein Elicits Highly Potent Immunity
  Anne-Catherine Fluckiger et al., Vaccine, (2021)
• Intranasal Plus Subcutaneous Prime Vaccination With a Dual Antigen COVID-19 Vaccine Elicits T-Cell and Antibody Responses in Mice
  Adrian Rice et al., Sci Rep, (2021)
• Change in Symptoms and Immune Response in People with Post-Acute Sequelae of SARS-Cov-2 Infection (PASC) After SARS-Cov-2 Vaccination
  Daisy Massay et al., MedRxiv, (2021)
• Evolution of SARS-CoV-2 Immune Responses in Nursing Home Residents Following Full Dose of the Comirnaty® COVID-19 Vaccine
  Giménez, E. et al., J Infect (2021)
• Correlates of Neutralization against SARS-CoV-2 Variants of Concern by Early Pandemic Sera
  Vidal, S-J. et al., J Virol, (2021)
• Preserved T-cell Response in anti-CD20 Treated Multiple Sclerosis Patients Following SARS-CoV-2 Vaccination
  Simon Faissner et al., Res Square, (2021)
• Durable T cell responses contrast with faster antibody waning in BNT162b2-vaccinated elderly at 6 month
  Laurent Renia et al., Res Square, (2021)
• SARS-CoV-2 ferritin nanoparticle vaccine induces robust innate immune activity driving polyfunctional spike-specific T cell responses
  Joshua M. Carmen et al., Vaccines, (2021)
• A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates
  M. Gordon Joyce et al., Science Translational Medicine
• SARS-CoV-2-Specific Cell-Mediated Immunity in Kidney Transplant Recipients Recovered From COVID-19
  Mario Fernández-Ruiz et al., Transplantation, (2021)
• SARS-CoV-2 Vaccination in Rituximab-Treated Patients: B Cells Promote Humoral Immune Responses in the Presence of T-Cell-Mediated Immunity
  Daniel Mrak et al., Ann Rheum Dis, (2021)
• Comorbid Illnesses are Associated With Altered Adaptive Immune Responses to SARS-CoV-2
  Krystle Kq Yu et al., JCI Insight, (2021)
• Longitudinal Analysis of Human Memory T-Cell Response According to the Severity of Illness up to 8 Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection
  Chang Kyung Kang et al., J Infect Dis, (2021)
• Deconvoluting the T Cell Response to SARS-CoV-2: Specificity Versus Chance and Cognate Cross-Reactivity
  Alexander A. Lehmann et al., Front Immunology, (2021)
• Identification of Conserved SARS-CoV-2 Spike Epitopes That Expand Public cTfh Clonotypes in Mild COVID-19 Patients
  Xiuyuan Lu et al., J Exp Med, (2021)
• Effectiveness of ChAdOx1 nCoV-19 Vaccine Against SARS-CoV-2 Infection During the Delta (B.1.617.2) Variant Surge in India: a Test-Negative, Case-Control Study and a Mechanistic Study of Post-Vaccination Immune Responses
  Ramachandran Thiruvengadam et al., Lancet Infect Dis, (2021)
• Acute Exercise Increases Immune Responses to SARS CoV-2 in a Previously Infected Man
  Baker, F. L. et al., Brain Behav Immun Health (2021)
• Generation of Glucocorticoid-Resistant SARS-CoV-2 T Cells for Adoptive Cell Therapy
  Basar et al, Cell Reports (2021)
• Peptide microarray based analysis of antibody responses to SARS-CoV-2 identifies unique epitopes with potential for diagnostic test development
  Holenya et a al, Eur J Immunol (2021)
• Immunogenicity of BNT162b2 mRNA COVID-19 Vaccine and SARS-CoV-2 Infection in Lung Transplant Recipients
  Havlin et al, Journal of Heart and Lung Transplantation (2021)
• COVID-19 Vaccine Candidates Based on Modified Vaccinia Virus Ankara Expressing the SARS-CoV-2 Spike Protein Induce Robust T- and B-Cell Immune Responses and Full Efficacy in Mice
  García-Arriaza et al, Journal of Virology (2021)
• Vaccination with SARS-CoV-2 Spike Protein and AS03 Adjuvant Induces Rapid Anamnestic Antibodies in the Lung and Protects Against Virus Challenge in Nonhuman Primates
  Francica et al, bioRxiv (2021)
• Impaired Anti-SARS-CoV-2 Humoral and Cellular Immune Response Induced by Pfizer-BioNTech BNT162b2 mRNA Vaccine in Solid Organ Transplanted Patients
  Miele et al, American Journal of Transplantation (2021)
• Therapeutic Antibodies, Targeting the SARS-CoV-2 Spike N-Terminal Domain, Protect Lethally Infected K18-hACE2 Mice
  Noy-Porat et al, iScience (2021)
• CD8+ T Cells Specific for an Immunodominant SARS-CoV-2 Nucleocapsid Epitope Cross-React With Selective Seasonal Coronaviruses
  Lineburg et al, Immunity (2021)
• Prime hAd5 Spike plus Nucleocapsid Vaccination Induces Ten-Fold Increases in Mean T-Cell Responses in Phase 1 Subjects that are Sustained Against Spike Variants
  Sieling et al, medRxiv (2021)
• SARS-CoV-2 Mutations in MHC-I-Restricted Epitopes Evade CD8+ T Cell Responses
  Agerer et al, Science Immunology (2021)
• Preclinical Evaluation of a SARS-CoV-2 mRNA Vaccine PTX-COVID19-B
  Liu et al, bioRxiv (2021)
• A Lymph Node-Targeted Amphiphile Vaccine Induces Potent Cellular and Humoral Immunity to SARS-CoV-2
  Steinbuck et al, Sci Adv. (2021)
• Neutralizing Monoclonal Anti-SARS-CoV-2 Antibodies Isolated from Immunized Rabbits Define Novel Vulnerable Spike-Protein Epitope
  Makdasi et al, Viruses (2021)
• SARS-CoV-2 Spike Glycoprotein Vaccine Candidate NVX-CoV2373 Immunogenicity in Baboons and Protection in Mice
  Tian et al, Nat Commun. (2021)
• Safety and Immunogenicity of the SARS-CoV-2 BNT162b1 mRNA Vaccine in Younger and Older Chinese Adults: a Randomized, Placebo-Controlled, Double-Blind Phase 1 Study
  Li et al, Nat Med. (2021)
• BNT162b Vaccines Protect Rhesus Macaques From SARS-CoV-2
  Vogel et al, Nature. (2021)
• Older Adults Lack SARS CoV-2 Cross-Reactive T Lymphocytes Directed to Human Coronaviruses OC43 and NL63
  Saletti et al, Sci Rep. (2021)
• SARS-CoV-2 Variants of Concern Partially Escape Humoral but not T-Cell Responses in COVID-19 Convalescent Donors and Vaccinees
  Geers et al, Sci Immunol. (2021)
• COVID-19 Immune Signatures Reveal Stable Antiviral T Cell Function Despite Declining Humoral Responses
  Bonifacius et al, Nat Commun. (2021)
• IL-33 Expression in Response to SARS-CoV-2 Correlates With Seropositivity in COVID-19 Convalescent Individuals
  Stanczak et al, Nat Commun. (2021)
• A Highly Specific Assay for the Detection of SARS-CoV-2-Reactive CD4 + and CD8 + T Cells in COVID-19 Patients
  Zelba et al, J Immunol. (2021)
• SARS-CoV-2-Reactive T Cells in Healthy Donors and Patients With COVID-19
  Braun et al, Nature (2021)
• Functional Characterization of CD4+ T Cell Receptors Crossreactive for SARS-CoV-2 and Endemic Coronaviruses
  Dykema et al, J Clin Invest. (2021)
• A Single-Dose Live-Attenuated YF17D-Vectored SARS-CoV-2 Vaccine Candidate
  Sanchez-Felipe et al, Nature (2021)
• SARS-CoV-2 Protein Subunit Vaccination of Mice and Rhesus Macaques Elicits Potent and Durable Neutralizing Antibody Responses
  Mandolesi et al, Cell Reports Medicine (2021)
• SARS-CoV-2 mRNA Vaccine BNT162b2 Elicited a Robust Humoral and Cellular Response Against SARSCoV-2 Variants
  Lilleri et al, Research Square (2021)
• SARS-CoV-2 Spike Protein Stabilized in The Closed State Induces Potent Neutralizing Responses
  Carnell et al, J Virol (2021)
• Robust SARS-CoV-2-specific T Cell Immunity is maintained at 6 Months Following Primary Infection
  Zuo et al, Nature (2021)
• First Report Demonstrating the Safety and Immunogenicity of the SARS-COV-2 BNT162b1 mRNA Vaccine in Younger and Older Chinese Adults: A Randomized, Placebo-Controlled, Observer-Blind Phase I Study
  Zhu et al, Research Square (2021)
• 1IL-2 and IFN-γ are Biomarkers of SARS-CoV-2 Specific Cellular Response in Whole Blood Stimulation Assays
  Pérez-Cabezas et al, medRxiv (2020)
• Adaptive Immune Responses to SARS-CoV-2 in Recovered Severe COVID-19 Patients
  Olea et al, medRxiv (2020)
• Persistent Cellular Immunity to SARS-CoV-2 Infection
  Breton et al, bioRxiv (2020)
• Deconvoluting the T cell response to SARS-CoV-2: specificity versus chance- and cognate cross-reactivity
  Lehmann et al, bioRxiv (2020)
• BNT162b2 Induces SARS-CoV-2-Neutralising Antibodies and T cells in Humans
  Sahin et al, medRxiv (2020)
• Convalescent Plasma Therapy for B-Cell Depleted Patients With Protracted COVID-19 Disease
  Hueso et al, Blood (2020)
• Divergent SARS‐CoV‐2‐Specific T and B Cell Responses in Severe but Not Mild COVID‐19 Patients
  Oja et al, European Journal of Immunology (2020)
• mRNA based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus neutralizing antibodies and mediates protection in rodents
  Rauch et al, bioRxiv (2020)
• T Cell and Antibody Responses to SARS-CoV-2: Experience From a French Transplantation and Hemodialysis Center During the COVID-19 Pandemic
  Candon et al, Am J Transplant (2020)
• Intrafamilial Exposure to SARS-CoV-2 Induces Cellular Immune Response without Seroconversion
  Gallais et al, Emerg Infect Dis (2020)
• A Glimpse Into the Diverse Cellular Immunity Against SARS-CoV-2
  Chang et al, Research Square (2020)
• Immunogenicity of novel mRNA COVID-19 vaccine MRT5500 in mice and 2 non-human primates
  Kalnin et al, bioRxiv (2020)
• Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in Older Adults
  Anderson et al, NEJM (2020)
• Divergent SARS-CoV-2-specific T and B cell Responses in Severe but Not Mild COVID-19
  Oja et al, bioRxiv (2020)
• Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates
  Corbett et al, New England J of Med (2020)
• Presence of SARS-CoV-2 reactive T cells in COVID-19 Patients and Healthy Donors
  Braun et al, Nature (2020)
• Single-shot Ad26 Vaccine Protects Against SARS-CoV-2 in Rhesus Macaques
  Mercado et al, Nature (2020)
• SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness
  Corbett et al, bioRxiv (2020)
• Data, Reagents, Assays and Merits of Proteomics for SARS-CoV-2 Research and Testing
  Zecha et al, Mol Cell Proteomics (2020)
• A Longitudinal Study of Immune Cells in Severe COVID-19 Patients
  Payen et al, medRXiv (2020)
• SARS-CoV-2-Specific T cells Exhibit Unique Features Characterized by Robust Helper Function, Lack of Terminal Differentiation, and High Proliferative Potential
  Neidleman et al, bioRxiv (2020)
• Generation of SARS-CoV-2 S1 Spike Glycoprotein Putative Antigenic Epitopes in vitro by Intracellular Aminopeptidases
  Stamatakis et al bioRxiv (2020)
• Self-Amplifying RNA SARS-CoV-2 Lipid Nanoparticle Vaccine Candidate Induces High Neutralizing Antibody Titers in Mice
  McKay et al, Nature (2020)
• An mRNA Vaccine Against SARS-CoV-2 — Preliminary Report
  Jackson et al, New England J of Med (2020)
• SARS‐CoV‐2‐Reactive Interferon‐γ‐producing CD8+ T cells in Patients Hospitalized with Coronavirus Disease 2019
  Giminez et al, J Med Vir (2020)
• Concurrent Human Antibody and TH1 type T-cell Responses 2 Elicited by a COVID-19 RNA Vaccine
  Sahin et al, medRXiv (2020)

Application Notes